Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(163)
•••
Comment by Sniper007on Feb 08, 2017 9:21pm
168 Views
Post# 25820320

RE:RE:RE:RE:RE:It has to be management

RE:RE:RE:RE:RE:It has to be management
I agree narmac. After all these years of waiting, why get your knickers in a knot now? I'm perfectly (well not perfectly - I'm feeling impatient like the rest of you) willing to wait until revenue comes in rather than giving up anything other than time. My belief is that we will begin to see revenue this quarter. The cost to do a trial without internal funds would be significant. Management has looked into it and have been seriously considering their options for some time now. Why wouldn't they have pulled the trigger already? My guess is they're expecting revenue to help cover the trials. Vaccinex's 1st milestone payment, assuming all went well, should be coming in soon and I would expect much, or at least a good portion of that revenue, to cover much of the cost of taking LSD or MTfp-Trastuzumab into the clinic. Sniper
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities